Last reviewed · How we verify

prolotherapy solution of 20% dextrose — Competitive Intelligence Brief

prolotherapy solution of 20% dextrose (prolotherapy solution of 20% dextrose) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Regenerative medicine agent. Area: Orthopedics / Musculoskeletal.

marketed Regenerative medicine agent Orthopedics / Musculoskeletal Small molecule Live · refreshed every 30 min

Target snapshot

prolotherapy solution of 20% dextrose (prolotherapy solution of 20% dextrose) — Hadassah Medical Organization. A 20% dextrose solution injected into damaged connective tissues stimulates a local inflammatory response that promotes tissue repair and regeneration.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
prolotherapy solution of 20% dextrose TARGET prolotherapy solution of 20% dextrose Hadassah Medical Organization marketed Regenerative medicine agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Regenerative medicine agent class)

  1. Hadassah Medical Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). prolotherapy solution of 20% dextrose — Competitive Intelligence Brief. https://druglandscape.com/ci/prolotherapy-solution-of-20-dextrose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: